[ad_1]
German pharmaceutical company BioNTech, which has developed a novel vaccine against Covid-19, will test a cancer treatment in Britain using the same mRNA technology, the company announced on Friday.
Up to 10,000 people will receive the immunotherapy tailored to individual tumors by the end of 2030, either in trials or as an approved treatment, BioNTech said in a statement.
The project is part of a new agreement with the UK government focused on “cancer immunotherapies, infectious disease vaccines and expanding BioNTech’s footprint in the UK”, the company said.
BioNTech will also open a new research and development center with approximately 70 employees in Cambridge, as well as a regional headquarters in London.
“Our goal is to accelerate the development of immunotherapies and vaccines using technologies that we have been studying for more than 20 years,” said Ugur Sahin, CEO and co-founder of BioNTech.
The UK “has successfully delivered Covid-19 vaccines so quickly”, he said, demonstrating “that drug development can be accelerated without cutting corners if everyone works seamlessly towards the same objective.
The messenger RNA method debuted with the Pfizer/BioNTech coronavirus vaccine, which was the first Covid vaccine to be approved in the West in late 2020.
Scientists believe that mRNA vaccines, which elicit an immune response by delivering genetic molecules containing the code for key elements of a pathogen into human cells, could be a game-changer against many diseases.
They also take less time to develop than traditional vaccines.
BioNTech’s Covid-19 vaccine was developed and approved by regulators in less than a year.
BioNTech is also working on mRNA-based vaccines against malaria, influenza and shingles.
The company has been developing mRNA-based cancer therapies since its inception in 2008 and they have been tested in several hundred people so far.
|
Sources 2/ https://www.breitbart.com/news/germanys-biontech-plans-uk-trial-of-mrna-cancer-therapy/ The mention sources can contact us to remove/changing this article |
[ad_2]